📈 Will you get serious about investing in 2025? Take the first step with 50% off InvestingProClaim Offer

Select Medical Holdings Corp executive chairman sells shares for $74.4 million

Published 11/29/2024, 06:57 PM
SEM
-

Robert A. Ortenzio, Executive Chairman of Select Medical Holdings Corp (NYSE:SEM), recently sold 3,804,805 shares of the company's common stock. The healthcare company, which has demonstrated strong financial health according to InvestingPro analysis, has seen its stock surge over 69% year-to-date. The shares were sold at an average price of $19.55 each, resulting in a total transaction value of approximately $74.4 million. Following this transaction, Ortenzio holds no shares directly under this particular trust, as the sale was conducted through the Rocco A. Ortenzio Separate Exempt Descendants Trust. Despite this sale, Ortenzio maintains indirect ownership of shares through other trusts. Trading at a P/E ratio of 9.85, InvestingPro analysis suggests the stock is fairly valued, with additional insights available in the comprehensive Pro Research Report covering this and 1,400+ other US stocks.

In other recent news, Select Medical Holdings Corporation reported a solid 6% growth in both consolidated revenue and adjusted EBITDA for the third quarter of 2024. The company also successfully launched the initial public offering (IPO) of Concentra, issuing over 23 million shares while still retaining a majority stake. They plan to distribute the remaining interest in Concentra to shareholders by the end of the year, depending on market conditions.

Select Medical's inpatient rehab division saw a 14% revenue increase and a 12% rise in adjusted EBITDA. The critical illness recovery division also reported a 3% revenue increase and a 9% rise in adjusted EBITDA. The company has a new 48-bed rehab hospital under development in Jacksonville, Florida, with more facilities planned in other states.

The company's earnings per share (EPS) increased to $0.43, up from $0.38 in Q3 2023. Select Medical also declared a cash dividend of $0.125. The company revised its 2024 revenue outlook to a range of $6.95 billion to $7.15 billion, with adjusted EBITDA projected between $865 million and $885 million. These are recent developments in Select Medical's financial performance and strategic plans.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.